Effects of Zortress® + Tacrolimus (everolimua) versus Standard Immunosuppression therapy on Progression of Coronary Artery Calcifications in Patients with Renal Transplantation

Grants and Contracts Details

StatusFinished
Effective start/end date12/16/1112/31/13

Funding

  • Novartis (domestic): $130,969.00